Evidence map›Paper›PMID 38702887›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2024

Chandipura viral glycoprotein (CNV-G) promotes Gectosome generation and enables delivery of intracellular therapeutics.

Xiaojuan Zhang, Quanbin Xu, Zeyu Liu, Jayson B Ball, Brandon Black, Saheli Ganguly, Michael E Harland, Samuel Blackman, Stephanie Bryant, Kristi Anseth and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaojuan ZhangDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA.
Quanbin XuDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA.
Zeyu LiuDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA.
Jayson B BallDepartment of Psychology & Neuroscience, and The Center for Neuroscience, University of Colorado, Boulder, CO 80309, USA.
Brandon BlackDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA.
Saheli GangulyDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA.
Michael E HarlandDepartment of Psychology & Neuroscience, and The Center for Neuroscience, University of Colorado, Boulder, CO 80309, USA.
Samuel BlackmanDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80309, USA; Materials Science & Engineering Program, University of Colorado, Boulder, CO 80309, USA; BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA.
Stephanie BryantDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80309, USA; Materials Science & Engineering Program, University of Colorado, Boulder, CO 80309, USA; BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA.
Kristi AnsethDepartment of Chemical and Biological Engineering, University of Colorado, Boulder, CO 80309, USA; Materials Science & Engineering Program, University of Colorado, Boulder, CO 80309, USA; BioFrontiers Institute, University of Colorado, Boulder, CO 80309, USA.
Linda WatkinsDepartment of Psychology & Neuroscience, and The Center for Neuroscience, University of Colorado, Boulder, CO 80309, USA.
Xuedong LiuDepartment of Biochemistry, University of Colorado, Boulder, CO 80303, USA. Electronic address: xuedong.liu@colorado.edu.

Funding

Programmable Microvesicles for Intracellular Macromolecule DeliveryR01GM144749 · NIGMS · UNIVERSITY OF COLORADO · PI XUEDONG LIU · 2022 to 2026
$3.2M
Opera Phenix High Throughput and High Content Confocal MicroscopeS10OD025072 · OD · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2018 to 2018
$1.1M
FACSAria Fusion Cell SorterS10OD021601 · OD · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2016 to 2016
$599k
NEUROTROPIC GECTOSOMES AS A CNS GENE DELIVERY SYSTEM FOR AD/ADRD THERAPY DEVELOPMENT75N95022C00020 · NIDA · VESICLE THERAPEUTICS INC. · PI ZHANG, GAN · 2022 to 2022
$475k
Development of a Gectosome Therapy for Cardiovascular DiseasesR41HL162212 · NHLBI · VESICLE THERAPEUTICS INC. · PI LIU, XUEDONG · 2022 to 2022
$317k
Neuron Specific mRNA Transfer With Fusogenic MicrovesiclesR03NS120072 · NINDS · UNIVERSITY OF COLORADO · PI LIU, XUEDONG · 2022 to 2023
$157k
NHLBI NIH HHS R41 HL162212NIDA NIH HHS 75N95022C00020NIGMS NIH HHS R01 GM144749NIH HHS S10 OD021601NIH HHS S10 OD025072NINDS NIH HHS R03 NS120072
6 · The paper itself

Abstract

Overexpression of vesicular stomatitis virus G protein (VSV-G) elevates the secretion of EVs known as gectosomes, which contain VSV-G. Such vesicles can be engineered to deliver therapeutic macromolecules. We investigated viral glycoproteins from several viruses for their potential in gectosome production and intracellular cargo delivery. Expression of the viral glycoprotein (viral glycoprotein from the Chandipura virus [CNV-G]) from the human neurotropic pathogen Chandipura virus in 293T cells significantly augments the production of CNV-G-containing gectosomes. In comparison with VSV-G gectosomes, CNV-G gectosomes exhibit heightened selectivity toward specific cell types, including primary cells and tumor cell lines. Consistent with the differential tropism between CNV-G and VSV-G gectosomes, cellular entry of CNV-G gectosome is independent of the Low-density lipoprotein receptor, which is essential for VSV-G entry, and shows varying sensitivity to pharmacological modulators. CNV-G gectosomes efficiently deliver diverse intracellular cargos for genomic modification or responses to stimuli in vitro and in the brain of mice in vivo utilizing a split GFP and chemical-induced dimerization system. Pharmacokinetics and biodistribution analyses support CNV-G gectosomes as a versatile platform for delivering macromolecular therapeutics intracellularly.

Indexed as

VesiculovirusAnimalsCell Line, TumorDrug Delivery SystemsExtracellular VesiclesGlycoproteinsHEK293 CellsHumansMembrane GlycoproteinsMiceViral Envelope ProteinsViral ProteinsGlycoproteinsG protein, vesicular stomatitis virusMembrane GlycoproteinsViral Envelope ProteinsViral ProteinsbiodistributioncatalaseChandipura virusCNV-Gexosomesgectosomesgenome editingmacromolecule deliverypharmacokineticsVSV-G

Identifiers

PMID38702887
PMCPMC11287003

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.